Vertex Pharmaceuticals announced that the European Commission has granted approval for the label expansion of KAFTRIO in a combination regimen with ivacaftor for the treatment of children with cystic fibrosis ages 2 through 5 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Biotech Alert: Searches spiking for these stocks today
- Vertex Pharmaceuticals, Crispr Therapeutics get MHRA authorization for Casgevy
- Vertex Pharmaceuticals price target raised to $400 from $390 at Piper Sandler
- Vertex Pharmaceuticals price target raised to $390 from $370 at TD Cowen
- Vertex Pharmaceuticals price target raised to $380 from $370 at Cantor Fitzgerald